The approval and increasing use of biological pharmaceuticals has propelled the pharmaceutical and supply chain management industries forward. These biologic drugs treat diabetes and cancer, as well as vaccinate against infectious diseases – providing new treatment options for certain patient populations. However, despite advances across the supply chain, these drugs remain vulnerable throughout the last mile.
This paper identifies the challenges of temperature-sensitive drug transportation and evaluates systems available to help reduce variability in order to preserve product quality and improve business efficiencies.
READ WHITE PAPER